MARKET

ALBO

ALBO

Albireo Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.91
-0.28
-0.93%
After Hours: 29.90 -0.01 -0.03% 19:56 05/07 EDT
OPEN
30.02
PREV CLOSE
30.19
HIGH
30.81
LOW
29.50
VOLUME
136.78K
TURNOVER
--
52 WEEK HIGH
49.00
52 WEEK LOW
22.08
MARKET CAP
574.10M
P/E (TTM)
-4.3608
1D
5D
1M
3M
1Y
5Y
DJ Albireo Pharma CEO Ron Cooper on Q1 2021 Results -- Earnings Call Transcript >ALBO
Dow Jones · 1d ago
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 07, May 07, 2021 (GLOBE NEWSWIRE via COMTEX) -- BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage...
GlobeNewswire · 1d ago
8-K: ALBIREO PHARMA, INC.
(EDGAR Online via COMTEX) -- 0001322505 false 0001322505 2021-05-06 2021-05-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
BRIEF-Albireo Reports Q1 Loss Per Share Of $2.29
reuters.com · 3d ago
ALBIREO PHARMA (ALBO) Reports Q1 Loss, Lags Revenue Estimates
Zacks.com · 3d ago
10-Q: ALBIREO PHARMA, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 3d ago
Albireo Pharma Q1 EPS $(2.29) Misses $(1.77) Estimate, Sales $2.00M Miss $2.13M Estimate
Albireo Pharma (NASDAQ:ALBO) reported quarterly losses of $(2.29) per share which missed the analyst consensus estimate of $(1.77) by 29.38 percent. This is a 2.69 percent decrease over losses of $(2.23) per share from
Benzinga · 3d ago
Albireo Reports Q1 Financial Results and Business Update
- Bylvay (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU-
GlobeNewswire · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALBO. Analyze the recent business situations of Albireo Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALBO stock price target is 72.86 with a high estimate of 82.00 and a low estimate of 65.00.
EPS
Institutional Holdings
Institutions: 147
Institutional Holdings: 19.68M
% Owned: 102.52%
Shares Outstanding: 19.19M
TypeInstitutionsShares
Increased
44
2.79M
New
22
305.76K
Decreased
30
1.22M
Sold Out
23
1.45M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Independent Director
David Chiswell
President/Chief Executive Officer/Director
Ronald Cooper
Chief Financial Officer/Treasurer
Simon Harford
Chief Human Resource Officer
Michelle Graham
Chief Scientific Officer
Jan Mattsson
General Counsel/Secretary
Jason Duncan
Other
Martha Carter
Other
Patrick Horn
Other
Pamela Stephenson
Independent Director
Michael Gutch
Independent Director
Roger Jeffs
Independent Director
Anne Klibanski
Independent Director
Stephanie Okey
Independent Director
Davey Scoon
No Data
About ALBO
Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).

Webull offers kinds of Albireo Pharma Inc stock information, including NASDAQ:ALBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALBO stock methods without spending real money on the virtual paper trading platform.